EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
+21.48%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$1.05B
AUM Growth
+$1.05B
(+25%)
Cap. Flow
+$66.2M
Cap. Flow
% of AUM
6.3%
Top 10 Holdings %
Top 10 Hldgs %
65.79%
Holding
77
New
14
Increased
23
Reduced
19
Closed
12
Top Buys
| 1 |
Natera
NTRA
|
$50.6M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
$31.1M |
| 3 |
Sanofi
SNY
|
$29.4M |
| 4 |
Biogen
BIIB
|
$21.4M |
| 5 |
GSK
GSK
|
$19.6M |
Top Sells
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$96.3M |
| 2 |
Community Health Systems
CYH
|
$29.5M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$23.3M |
| 4 |
Lantheus
LNTH
|
$14.6M |
| 5 |
ABMD
Abiomed Inc
ABMD
|
$13M |
Sector Composition
| 1 | Healthcare | 97.4% |
| 2 | Communication Services | 0.84% |
| 3 | Financials | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
GSK
GSK
$79.9B
| $124M | 10.84% | 3,490,457 +551,387 | +19% | +$19.6M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $121M | 10.61% | 1,064,446 -205,145 | -16% | -$23.3M |
|
|
3
Natera
NTRA
$23.1B
| $108M | 9.45% | 2,685,959 +1,260,357 | +88% | +$50.6M |
|
|
4
Sanofi
SNY
$121B
| $77.7M | 6.8% | 1,603,348 +607,313 | +61% | +$29.4M |
|
5
United Therapeutics
UTHR
$13.8B
| $64.7M | 5.67% | 232,787 -22,439 | -9% | -$6.24M |
|
6
Danaher
DHR
$147B
| $43.2M | 3.78% | 162,571 +25 | +0% | +$6.64K |
|
7
Teva Pharmaceuticals
TEVA
$21.1B
| $43M | 3.76% | 4,712,597 +649,662 | +16% | +$5.92M |
|
8
Syndax Pharmaceuticals
SNDX
$1.41B
| $41.2M | 3.61% | 1,620,713 +409,279 | +34% | +$10.4M |
|
|
9
Biogen
BIIB
$19.4B
| $38M | 3.33% | 137,348 +77,204 | +128% | +$21.4M |
|
|
CTLT
10
DELISTED
CATALENT, INC.
CTLT
| $31.1M | 2.73% | +691,677 | New | +$31.1M |
|
11
Illumina
ILMN
$15.8B
| $28.3M | 2.48% | 140,067 +33,065 | +31% | +$6.69M |
|
12
Celldex Therapeutics
CLDX
$1.47B
| $24.9M | 2.18% | 558,774 -67,598 | -11% | -$3.01M |
|
13
Envista
NVST
$3.52B
| $21.6M | 1.89% | 642,405 +9,404 | +1% | +$317K |
|
14
SPDR S&P Biotech ETF
XBI
$5.07B
| $17.9M | 1.57% | 216,087 +116,087 | +116% | +$9.64M |
|
15
Centene
CNC
$14.3B
| $17.6M | 1.54% | 214,561 +23,253 | +12% | +$1.91M |
|
16
Haleon
HLN
$43.9B
| $15.1M | 1.32% | +1,881,470 | New | +$15.1M |
|
17
Elevance Health
ELV
$71.8B
| $14.4M | 1.26% | 28,042 -4,998 | -15% | -$2.56M |
|
18
Icon
ICLR
$13.8B
| $13M | 1.13% | 66,693 +56,481 | +553% | +$11M |
|
19
Avantor
AVTR
$9.18B
| $12.7M | 1.11% | 600,200 +525,748 | +706% | +$11.1M |
|
20
Tenet Healthcare
THC
$16.3B
| $12.4M | 1.09% | +254,586 | New | +$12.4M |
|
21
Seres Therapeutics
MCRB
$166M
| $12.3M | 1.08% | 2,200,999 +265,174 | +14% | +$1.48M |
|
22
Xenon Pharmaceuticals
XENE
$2.98B
| $10.9M | 0.95% | 275,704 +16,092 | +6% | +$635K |
|
23
Humana
HUM
$36.5B
| $10.7M | 0.94% | 20,911 -3,661 | -15% | -$1.88M |
|
24
BioCryst Pharmaceuticals
BCRX
$1.74B
| $10.1M | 0.89% | +880,487 | New | +$10.1M |
|
25
Repligen
RGEN
$6.88B
| $9.65M | 0.85% | 57,004 +53,363 | +1,466% | +$9.03M |
|